BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 23118780)

  • 21. Differential diagnosis of Crohn's disease using antibodies to glycoprotein 2 and Saccharomyces cerevisiae.
    Duman AE; Hülagü S; Çelebi A; Korkmaz U; Musul MM; Şentürk Ö; Şirin G; Yılmaz H; Koç DÖ; Dindar G; Öztürkler M; Bozkurt N; Kır HM
    Turk J Gastroenterol; 2019 Jan; 30(1):21-27. PubMed ID: 30465525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
    Cummings D; Cruise M; Lopez R; Roggenbuck D; Jairath V; Wang Y; Shen B; Rieder F
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1251-1259. PubMed ID: 30411391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pancreatic anti-GP2 and anti-Saccharomyces cerevisiae antibodies in ruminants with paratuberculosis: A better understanding of the immunopathogenesis of Crohn's disease.
    Liaskos C; Gkoutzourelas A; Spyrou V; Koutsoumpas A; Athanasiou LV; Amiridis GS; Billinis C; Bogdanos DP
    Clin Res Hepatol Gastroenterol; 2020 Oct; 44(5):778-785. PubMed ID: 32035824
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
    Caneparo V; Pastorelli L; Pisani LF; Bruni B; Prodam F; Boldorini R; Roggenbuck D; Vecchi M; Landolfo S; Gariglio M; De Andrea M
    Inflamm Bowel Dis; 2016 Dec; 22(12):2977-2987. PubMed ID: 27636380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-Outer membrane protein C and anti-glycoprotein 2 antibodies in inflammatory bowel disease and their association with complicated forms of Crohn's disease.
    Kohoutova D; Drahosova M; Moravkova P; Rejchrt S; Bures J
    BMC Gastroenterol; 2014 Dec; 14():190. PubMed ID: 25551469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diagnostic and clinical significance of antigen-specific pancreatic antibodies in inflammatory bowel diseases: A meta-analysis.
    Gkiouras K; Grammatikopoulou MG; Theodoridis X; Pagkalidou E; Chatzikyriakou E; Apostolidou AG; Rigopoulou EI; Sakkas LI; Bogdanos DP
    World J Gastroenterol; 2020 Jan; 26(2):246-265. PubMed ID: 31988587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibodies Against Glycoprotein 2 Are Specific Biomarkers for Pediatric Crohn's Disease.
    Shpoliansky M; Roggenbuck D; Pinsker M; Salamon N; Weiss B; Shouval DS; Werner L
    Dig Dis Sci; 2021 Aug; 66(8):2619-2626. PubMed ID: 32886311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Autoimmunity in Crohn's Disease-A Putative Stratification Factor of the Clinical Phenotype.
    Roggenbuck D; Reinhold D; Baumgart DC; Schierack P; Conrad K; Laass MW
    Adv Clin Chem; 2016; 77():77-101. PubMed ID: 27717419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human glycoprotein-2 expressed in Brunner glands - A putative autoimmune target and link between Crohn's and coeliac disease.
    Roggenbuck D; Goihl A; Sowa M; Lopens S; Rödiger S; Schierack P; Conrad K; Sommer U; Jöhrens K; Grützmann R; Reinhold D; Laass MW
    Clin Immunol; 2023 Feb; 247():109214. PubMed ID: 36608744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-high mobility group box 1 and box 2 non-histone chromosomal proteins (HMGB1/HMGB2) antibodies and anti-Saccharomyces cerevisiae antibodies (ASCA): accuracy in differentially diagnosing UC and CD and correlation with inflammatory bowel disease phenotype.
    Takaishi H; Kanai T; Nakazawa A; Sugata F; Nikai A; Yoshizawa S; Hamamoto Y; Funakoshi S; Yajima T; Iwao Y; Takemura M; Ozaki S; Hibi T
    J Gastroenterol; 2012 Sep; 47(9):969-77. PubMed ID: 22644337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antineutrophil antibodies in inflammatory bowel disease recognize different antigens.
    Mulder AH; Broekroelofs J; Horst G; Limburg PC; Nelis GF; Kallenberg CG
    Adv Exp Med Biol; 1993; 336():519-22. PubMed ID: 8296668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distinct patterns of immunoglobulin classes and IgG subclasses of autoantibodies in patients with inflammatory bowel disease.
    Müller-Ladner U; Gross V; Andus T; Gschwendtner H; Roth M; Caesar I; Schölmerich J; Lang B
    Eur J Gastroenterol Hepatol; 1996 Jun; 8(6):579-84. PubMed ID: 8823574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.
    Laass MW; Röber N; Range U; Noß L; Roggenbuck D; Conrad K
    PLoS One; 2015; 10(6):e0128104. PubMed ID: 26047356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
    Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levels of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor, Including IgA Isotypes, and Articular Manifestations in Ulcerative Colitis and Crohn's Disease.
    Janssen KMJ; Hop H; Vissink A; Dijkstra G; de Smit MJ; Brouwer E; Westra J
    Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33139618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dietary antigens in Crohn's disease: antibodies to porcine pancreatic amylase.
    Suzuki H; Fukuda Y; Koizuka H; Tomita T; Hori K; Suzuki M; O'Morain C
    Am J Gastroenterol; 2008 Mar; 103(3):656-64. PubMed ID: 18028509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease.
    Koutroubakis IE; Drygiannakis D; Karmiris K; Drygiannakis I; Makreas S; Kouroumalis EA
    Dig Dis Sci; 2005 Dec; 50(12):2330-4. PubMed ID: 16416183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.
    Lakatos PL; Altorjay I; Szamosi T; Palatka K; Vitalis Z; Tumpek J; Sipka S; Udvardy M; Dinya T; Lakatos L; Kovacs A; Molnar T; Tulassay Z; Miheller P; Barta Z; Stocker W; Papp J; Veres G; Papp M;
    Inflamm Bowel Dis; 2009 Mar; 15(3):365-74. PubMed ID: 18972554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity.
    Broekroelofs J; Mulder AH; Nelis GF; Westerveld BD; Tervaert JW; Kallenberg CG
    Dig Dis Sci; 1994 Mar; 39(3):545-9. PubMed ID: 7510606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases.
    Op De Beéck K; Vermeire S; Rutgeerts P; Bossuyt X
    Gut; 2012 Jan; 61(1):162-4; author reply 164-5. PubMed ID: 21193445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.